Go to
JCI Insight
Citations to this article
Antonio Castrillo, Peter Tontonoz
Published December 1, 2004
Citation Information: J Clin Invest. 2004;114(11):1538-1540. https://doi.org/10.1172/JCI23705.
Citation Information: J Clin Invest. 2004;114(11):1538-1540. https://doi.org/10.1172/JCI23705.
Abstract
Cardiovascular disease is the leading cause of morbidity and mortality in Western countries. Previous studies have highlighted the beneficial effects of PPARγ activators on cardiovascular disease; however, the role of other PPAR family members in atherosclerosis is less clear. A report in this issue of the JCI expands our understanding of PPARs in vascular biology and highlights the potential use of multiple PPAR agonists to limit lipid accumulation in macrophages.
Authors
Antonio Castrillo, Peter Tontonoz
Total citations by year
Citation information
Citations to this article in year 2017 (2)
| Title and authors | Publication | Year |
|---|---|---|
|
Smooth muscle cell-specific deletion of Col15a1 unexpectedly leads to impaired development of advanced atherosclerotic lesions
BG Durgin, OA Cherepanova, D Gomez, T Karaoli, GF Alencar, JT Butcher, YQ Zhou, MP Bendeck, BE Isakson, GK Owens, JJ Connelly |
American journal of physiology. Heart and circulatory physiology | 2017 |
|
PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α
L Han, WJ Shen, S Bittner, FB Kraemer, S Azhar |
Future Cardiology | 2017 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)